Skip to content
  • News
  • Insights
  • Interviews
  • Reports
  • Newsletter
Main Menu
  • News
  • Insights
  • Interviews
  • Reports
  • Newsletter

About Me

Nick Mars - Lorem ipsum dolor sit amet, consectetur adipisicing elit. Minima incidunt voluptates nemo, dolor optio quia architecto quis delectus perspiciatis. Nobis atque id hic neque possimus voluptatum voluptatibus tenetur, perspiciatis consequuntur.

Social Icons

Facebook1,750FansLikeX (Twitter)759FollowersFollowInstagram2,500FollowersFollowPinterest1,365FollowersPinYoutube2,700SubscribersSubscribeTiktok2,900FollowersFollowTelegram2,000MembersJoinSoundcloud1,963FollowersFollowVimeo1,254FollowersFollowDribbble3,520FollowersFollow
  • Support
    • Documentation
    • Documentation
    • Video Tutorials
    • Video Tutorials
    • Support Forums
    • Support
  • Support
  • About Theme
  • About theme
  • Visit Us
  • Visit Us
Wednesday, June 24, 2026

Arisa Smith

  • Manufacturing
  • Opinions
  • R&D

Beyond ESG: Is Sustainability Becoming a Core Pharma Strategy in Healthcare?

Sustainability in the pharmaceutical industry is evolving beyond environmental, social, and governance reporting into a broader strategic priority. What was once viewed primarily as a corporate respon...

Arisa Smith
May 12, 2026
Read More
  • Editor's Pick
  • Latest Updates
  • Opinions
  • Technology

Pharma and AI Partnerships: Collaboration Boom or Dependency Risk in Healthcare?

Artificial intelligence is rapidly becoming embedded across the pharmaceutical value chain, from drug discovery and clinical trial optimization to manufacturing and commercialization. As the technolog...

Arisa Smith
May 12, 2026
Read More
  • Manufacturing
  • Opinions

Cell and Gene Therapy Manufacturing: The Industry’s Biggest Bottleneck in Healthcare?

Cell and gene therapies are redefining the future of medicine, offering the possibility of long term remission and even cures for diseases once considered untreatable. Yet despite this scientific prom...

Arisa Smith
May 12, 2026
Read More
  • Opinions
  • Technology

Data Is the New Drug: Who Will Control the Future of Healthcare Intelligence?

Healthcare is entering an era where data may become as strategically valuable as the therapies themselves. From clinical trials and wearable devices to electronic health records and genomic sequencing...

Arisa Smith
May 12, 2026
Read More
  • Opinions
  • R&D

The Obesity Drug Gold Rush: Healthcare Breakthrough or Market Frenzy? 

The Obesity Drug Gold Rush: Healthcare Breakthrough or Market Frenzy? The global pharmaceutical industry is witnessing an unprecedented surge in demand for obesity therapies, transforming what was onc...

Arisa Smith
May 12, 2026
Read More
  • Opinions
  • Regulatory

The Patent Cliff Returns: Can Pharma Outrun Billions in Lost Exclusivity?

The pharmaceutical industry is once again approaching a major patent cliff, with several blockbuster therapies set to lose exclusivity over the next few years. For many companies, these products have ...

Arisa Smith
May 12, 2026
Read More
  • News
  • Regulatory

Health Canada authorizes iStatis Hepatitis B Surface Antigen Test by bioLytical Laboratories, marking a North American first 

Takeaways:   This authorization makes iStatis the first rapid point‑of‑care HBsAg test cleared in both Canada and North America, giving frontline providers a 15‑minute to...

Arisa Smith
May 5, 2026
Read More
  • Companies
  • News

BC PharmaCare adds coverage for REVESTIVE (teduglutide) by Takeda Canada Inc. for SBS patients in British Columbia 

Takeaways:  BC’s decision makes REVESTIVE a province‑funded option for both adult and pediatric Short Bowel Syndrome patients who depend on parenteral support, align...

Arisa Smith
May 5, 2026
Read More
  • Companies
  • News

CELYSTRA Pharma launches in Quebec with >$20M backing and first rare disease therapy approved by Health Canada 

Takeaways:  CELYSTRA is being set up as a dedicated Canadian “importer–operator” for advanced rare‑disease drugs, starting with RNA therapeutics. It’s led by senior ex‑big‑pha...

Arisa Smith
May 5, 2026
Read More
  • News
  • Regulatory

Health Canada approves Kisunla (donanemab) by Lilly Canada for early Alzheimer’s disease 

Takeaways:  Kisunla adds a new money‑maker for Lilly in Canada, but real sales will depend on how fast the system can diagnose patients early and pay for the drug.  Because testing and speci...

Arisa Smith
May 4, 2026
Read More
1...5678910
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Minima incidunt voluptates nemo, dolor optio quia architecto quis delectus perspiciatis.

Nobis atque id hic neque possimus voluptatum voluptatibus tenetur, perspiciatis consequuntur.

Email: sample@gmail.com
Call Us: +987 95 95 64 82

Category List

  • Commercial(11)
  • Companies(13)
  • Deals(5)
  • Editor's Pick(5)
  • Latest Updates(1)
  • Manufacturing(6)
  • Must Read(4)
  • News(66)
  • Opinions(30)
  • Public Health(10)
  • R&D(12)
  • Regulatory(38)
  • Technology(8)

Featured Posts

1
AbbVie’s Boey Approved in Canada for Glabellar Lines 
June 24, 2026
2
Roche’s Itovebi Moves Closer to Public Access in Canada 
June 24, 2026
3
Takeda’s Zasocitinib Beats Deucravacitinib in Psoriasis Phase 3 Trial 
June 24, 2026
Copyright © 2026 | Powered by News Magazine X